Pharma, not high-tech, concerns now dominate US patent politics
The first pronouncements from new USPTO Director Kathi Vidal are the latest indication that the centre of gravity in IP debate and policy-making has shifted significantly
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.